Glaukos At Glaukos we are focused on pioneering new treatments for chronic eye diseases. Innovation is at the core of everything we do.

Our mission at Glaukos is to truly transform vision by pioneering novel platforms that can meaningfully advance the standard of care and improve outcomes for patients suffering from sight-threatening chronic eye diseases. Our mantra “We’ll Go First” embodies our commitment and determination to take chances and push the limits of science and technology to disrupt and improve the legacy treatment pa

radigms in glaucoma, corneal disorders and retinal diseases. ​

​Please note when clicking links in our content you will be led outside of the Glaukos page. The site you opt to connect to does not adhere to our privacy policy. You are solely responsible for your interactions on outside websites. ​

Important Safety Information​
https://www.glaukos.com/important-safety-information/

​COMMUNITY GUIDELINES: ​
Glaukos welcomes interactions and will respond to questions, comments and feedback, but responses may be delayed or limited. ​

Posts and comments contain the opinions and views of other users and Glaukos is not responsible for their accuracy or reliability. ​

​Do not post about financial, legal and regulatory issues, unsubstantiated claims about products, profanity, defamatory, offensive, discriminatory or demeaning content, threats, violence, illegal behavior, health or medical advice, false or misleading information, personal health information, or proprietary, confidential or sensitive information. ​

Follow Facebook's posting guidelines and terms of use. ​

By participating, you promise to comply with these guidelines, but we reserve the right to remove any posts that do not comply. Continuous violations may result in removal from the follower list and inability to receive news, comment or message/contact us. ​

Disclaimers: ​
Accounts followed by or following Glaukos social media channels do not indicate endorsement of the account, their products and services or content they publish. ​

Glaukos may provide links or references to other sites as part of its content, but it does not take responsibility for the content from those sites and shall not be liable for damages or injuries arising from it. These links are provided as a convenience only. ​

Glaukos reserves all rights to the channels, including the right to add, remove or modify content, discontinue the account, accept/reject followers and respond to comments. ​

Only Glaukos and its authorized users may represent Glaukos. Any other representation of Glaukos without authorization will result in legal action. ​

​Medical Side Effects/Adverse Events: ​
If you believe you have experienced any medical side effects or reactions from the Glaukos iLink cross-linking procedure or iStent portfolio of products, consult your physician or healthcare professional and report it to Glaukos by calling 1-844-528-3376, Option 1 or by contacting the FDA at 1-800-FDA-1088. ​

​Avoid sharing personal health information on social media channels, but if you do share information about any side effects, Glaukos may contact you for more information. Posts about side effects may be removed from our channels due to legal requirements. ​

Glaukos will not store or use your personal information, but if you report any adverse events or product issues, we need to store and use identifying information about you to submit it to Glaukos and/or regulatory authorities. ​

​Please be aware that Facebook also has access to information shared on our channels, refer to Facebook's Privacy Policy for more details. ​

Tomorrow marks Global Interventional Glaucoma Day! We are excited to be in London alongside ophthalmic leaders to discus...
09/11/2026

Tomorrow marks Global Interventional Glaucoma Day!

We are excited to be in London alongside ophthalmic leaders to discuss moving beyond conventional glaucoma care. For decades, managing glaucoma meant relying on a "watch and wait" approach by holding off on procedural options until disease progression occurred. Today, procedural and pharmaceutical advancements empower clinicians to intervene earlier, taking control of high eye pressure and protecting sight proactively.

Joining us for the ESCRS Congress? Don't miss our official symposium, "Why Are We Still Watching and Waiting?", featuring an international panel of experts sharing the data behind proactive intervention. Together, we are transforming vision and redefining the standard of care worldwide.

Learn more about our commitment to interventional glaucoma at glaukos.com.

09/10/2026

Daily topical regimens present well-documented challenges. With an interventional approach, eye care professionals can address elevated intraocular pressure proactively, mitigating patient drop reliance and taking control of disease progression earlier in the treatment journey

Explore how proactive procedural options fit into your clinical practice to help preserve long-term visual function and learn more about shifting the glaucoma paradigm at interventionalglaucoma.com

For years, glaucoma care relied on a "watch and wait" approach. Today, the interventional movement is here.Interventiona...
09/09/2026

For years, glaucoma care relied on a "watch and wait" approach. Today, the interventional movement is here.

Interventional Glaucoma empowers clinicians to move beyond traditional drop-first protocols and take control of the disease earlier in the treatment journey, helping to protect patients’ sight and preserve their independence. Throughout September, we’re celebrating by sharing insights, clinical data, and stories behind this new way to manage glaucoma.

🔗 Explore the interventional movement at https://go.glaukos.com/ESCRS-London.

We shouldn’t have to wait for vision loss to escalate before taking action. By advancing early intervention, we aim to e...
09/09/2026

We shouldn’t have to wait for vision loss to escalate before taking action. By advancing early intervention, we aim to empower eye care professionals to redefine the trajectory of glaucoma care from day one.

We believe our greatest strength is empowering our people. Through continuous investments in education, we remain dedica...
09/04/2026

We believe our greatest strength is empowering our people. Through continuous investments in education, we remain dedicated to developing the individuals who bring our vision to life every day.

09/03/2026

In just a few days, the ophthalmology community gathers at – and Glaukos will be right in the middle of it.

From new perspectives on glaucoma care to hands-on experiences with iStent infinite® – we can't wait to reconnect, exchange ideas, and keep pushing what's possible in glaucoma.

Come and join us in London!

Find out more: https://bit.ly/4ibJSuc

Watch the end of the video for important safety information about iStent Infinite®.



©2026 Glaukos® Corporation. All rights reserved. PM-EU-0465

Managing eye pressure is only effective when patients can maintain their daily regimens. Our approach considers human be...
08/31/2026

Managing eye pressure is only effective when patients can maintain their daily regimens. Our approach considers human behavior to support long-term control.

Mentorship programs play a vital role in shaping the next generation of eye care professionals. We are proud to highligh...
08/29/2026

Mentorship programs play a vital role in shaping the next generation of eye care professionals. We are proud to highlight our very own Medical Science Liaison, Dr. Roselyn Ahua. Her selection as a 2025 Ophthalmic World Leaders Fellow demonstrates a commitment to developing the next generation of ophthalmology leaders.

08/11/2026

Glaukos was highlighted in Times Square in celebration of Glaukos Day on June 25th! 👁️✨

We were thrilled to light up the city as a proudly listed New York Stock Exchange company. Milestones like this are a direct reflection of the passion, brilliant culture, and dedication of our global Glaukos family. Every day, our teams work at the intersection of science and empathy to create a new era of interventional eye care.

Sustainable care includes how we ship our treatments. When Epioxa (riboflavin 5′-phosphate ophthalmic solution) launches...
07/31/2026

Sustainable care includes how we ship our treatments. When Epioxa (riboflavin 5′-phosphate ophthalmic solution) launches commercially, the packaging is shifting to a single-use recyclable system. Here's the annual impact. 🍃

Address

1 Glaukos Way
Aliso Viejo, CA
92656

Alerts

Be the first to know and let us send you an email when Glaukos posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share